electroCore, Inc. (ECOR)
After hours:
Chart Events
Performance Outlook
| Previous Close | 4.29 |
| Open | 4.39 |
| Bid | 5.33 x 1100 |
| Ask | 5.34 x 800 |
| Day's Range | 4.31 - 5.64 |
| 52 Week Range | 2.92 - 10.50 |
| Volume | |
| Avg. Volume | 24,992 |
| Market Cap | 25.325M |
| Beta (5Y Monthly) | 1.10 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.21 |
| Earnings Date | May 03, 2023 - May 08, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 23.67 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for ECOR
Related Research
- electroCore, Inc.Technical Assessment: Bullish in the Intermediate-TermOn Monday, the stock market maintained its strength from Friday -- and with a little luck has some room to run. The SPX rose almost 1%, while the Dow (which had been leading of late) tacked on 1.3% and popped back above its declining 200-day (as it did in August for a couple of days). Elsewhere, the Nasdaq gained 0.9% and the QQQs added 1.1%. Treasury yields across the curve rose and are back near recent highs, but the U.S. Dollar Index fell. Since late September, the dollar is working on two lower highs and is close to a second lower low.RatingFair ValueEconomic Moat5 months agoArgus Research
- GlobeNewswire
electroCore Reports Results of Pre-Clinical Trial in a Model of Traumatic Brain Injury
Pre-clinical trial demonstrates the ability of nVNS to decrease the amount of brain injury, decrease anxiety and improve motor function post injuryROCKAWAY, N.J., March 23, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the publication of a paper entitled “Non-Invasive Vagus Nerve Stimulation Improves Brain Lesion Volume and Neurobehavioral Outcomes in a Rat Model of Traumatic Brain Injury” in the peer-re
- GlobeNewswire
electroCore's Truvaga Users Reported Improved Stress, Anxiety, Sleep, Energy and Mood in Recent Focus Group Study
ROCKAWAY, N.J., March 21, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the results of a TruvagaTM focus group study conducted earlier this year. Based on a 30-day in-home use test by an independent third-party research firm, the Truvaga product helped its users improve stress, anxiety, sleep, energy, and mood.In the in-home focus group study, 34 participants were instructed to use the T
- GlobeNewswire
electroCore Affirms No Direct Exposure to Silicon Valley Bank, Silvergate Bank, or Signature Bank
ROCKAWAY, N.J., March 14, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today it does not have direct exposure to Silicon Valley Bank, Silvergate Bank, or Signature Bank. electroCore does not hold cash deposits or securities with these banking institutions, and currently holds corporate cash accounts with large global money center banks.About electroCore, Inc.electroCore, Inc. is a commercial stage bioelectron
